{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:30:40Z","timestamp":1793788240991,"version":"4.6.1"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.biopha.2024.116312","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T06:30:14Z","timestamp":1709015414000},"page":"116312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer"],"prefix":"10.1016","volume":"173","author":[{"given":"Junping","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2024.116312_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57080749","article-title":"Bladder cancer: current challenges and future directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Medicina"},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.biopha.2024.116312_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093360","article-title":"Diagnostic and prognostic potential of biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in bladder cancers","volume":"21","author":"Matuszczak","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage Urothelial Carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2024.116312_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","article-title":"Advances in bladder cancer biology and therapy","volume":"21","author":"Tran","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"7679","key":"10.1016\/j.biopha.2024.116312_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/551S34a","article-title":"Unlocking bladder cancer","volume":"551","author":"Berdik","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2024.116312_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104154","article-title":"Appraising the causal role of smoking in multiple diseases: a systematic review and meta-analysis of Mendelian randomization studies","volume":"82","author":"Larsson","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2024.116312_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fonc.2020.00102","article-title":"Traditional classification and novel subtyping systems for bladder cancer","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib13","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ijc.32556","article-title":"Proteome-based classification of nonmuscle invasive bladder cancer","volume":"146","author":"Stroggilos","year":"2020","journal-title":"Int J. Cancer"},{"issue":"21","key":"10.1016\/j.biopha.2024.116312_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215537","article-title":"Proteomics as a Complementary Technique to Characterize Bladder Cancer","volume":"13","author":"L\u00f3pez-Cort\u00e9s","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biopha.2024.116312_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"7492","key":"10.1016\/j.biopha.2024.116312_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Network","year":"2014","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.biopha.2024.116312_bib18","first-page":"4514","article-title":"Invasive bladder cancer: genomic insights and therapeutic promise","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res.\u00a0Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116312_bib21","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.4238\/2015.April.27.6","article-title":"CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis","volume":"14","author":"Kuang","year":"2015","journal-title":"Genet Mol. Res."},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000107582","article-title":"Cytokeratin markers come of age","volume":"28","author":"Linder","year":"2007","journal-title":"Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1535370218754493","article-title":"Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis","volume":"243","author":"Li","year":"2018","journal-title":"Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib24","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s13277-015-3352-z","article-title":"Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Huang","year":"2015","journal-title":"Tumour Biol.\u00a0J. Int. Soc. Oncodev. Biol. Med."},{"issue":"11","key":"10.1016\/j.biopha.2024.116312_bib25","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/cncr.10565","article-title":"Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma","volume":"94","author":"Nisman","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib26","first-page":"2651","article-title":"Preliminary results of a multicentre study of the UBC rapid test for detection of urinary bladder cancer","volume":"35","author":"Ecke","year":"2015","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061520","article-title":"Non-invasive biomarkers in the diagnosis of upper urinary tract urothelial carcinoma-a systematic review","volume":"14","author":"Bia\u0142ek","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib28","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0090-4295(01)01307-3","article-title":"The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma","volume":"58","author":"Walsh","year":"2001","journal-title":"Urology"},{"issue":"12","key":"10.1016\/j.biopha.2024.116312_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis","volume":"163","author":"Chou","year":"2015","journal-title":"Ann. Intern Med."},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00345-012-0935-9","article-title":"Urinary BTA: indicator of bladder cancer or of hematuria","volume":"30","author":"Miyake","year":"2012","journal-title":"World J. Urol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib31","first-page":"375","article-title":"Sandwich ELISA for detecting urinary Survivin in bladder cancer","volume":"25","author":"Li","year":"2013","journal-title":"Chin. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116312_bib32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s12253-019-00678-1","article-title":"Intensity of nuclear staining for Ki-67, p53 and survivin as a new prognostic factor in non-muscle invasive bladder cancer","volume":"26","author":"Stec","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.biopha.2024.116312_bib33","article-title":"The establishment of quantitatively regulating expression cassette with sgRNA Targeting BIRC5 to elucidate the synergistic pathway of survivin with P-glycoprotein in cancer multi-drug resistance","volume":"9","author":"Deng","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1464-410X.2011.10884.x","article-title":"Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review","volume":"110","author":"Ku","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib35","first-page":"7","article-title":"Prognostic significance of survivin, \u03b2-catenin and p53 expression in urothelial carcinoma","volume":"15","author":"Senol","year":"2015","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"23","key":"10.1016\/j.biopha.2024.116312_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312864","article-title":"Microsatellite instability analysis (MSA) for bladder cancer: past history and future directions","volume":"22","author":"Moon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010209","article-title":"Qualification of the microsatellite instability analysis (MSA) for bladder cancer detection: the technical challenges of concordance analysis","volume":"25","author":"Reynolds","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.biopha.2024.116312_bib38","first-page":"5620","article-title":"Microsatellite instability in bladder cancer","volume":"53","author":"Gonzalez-Zulueta","year":"1993","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0302-2838(03)00059-9","article-title":"Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy","volume":"43","author":"van Rhijn","year":"2003","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib40","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4103\/jcrt.JCRT_346_13","article-title":"Assessment of microsatellite instability for screening bladder cancer in high-risk population","volume":"14","author":"Wadhwa","year":"2018","journal-title":"J. Cancer Res. Ther."},{"issue":"18","key":"10.1016\/j.biopha.2024.116312_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814374","article-title":"Molecular markers for bladder cancer screening: an insight into bladder cancer and FDA-approved biomarkers","volume":"24","author":"Flores Monar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.biopha.2024.116312_bib42","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.7150\/thno.44634","article-title":"Urine biopsy technologies: cancer and beyond","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2024.116312_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2147\/OTT.S283891","article-title":"The development of non-invasive diagnostic tools in bladder cancer","volume":"15","author":"Schulz","year":"2022","journal-title":"Onco Targets Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib44","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CU9.0000000000000012","article-title":"Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review","volume":"15","author":"Sciarra","year":"2021","journal-title":"Curr. Urol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.295.3.299","article-title":"Surveillance for recurrent bladder cancer using a point-of-care proteomic assay","volume":"295","author":"Grossman","year":"2006","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib46","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.juro.2014.05.087","article-title":"Prospective external validation of a bladder cancer detection model","volume":"192","author":"Lotan","year":"2014","journal-title":"J. Urol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116312_bib47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","article-title":"Detection of bladder cancer using a point-of-care proteomic assay","volume":"293","author":"Grossman","year":"2005","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.biopha.2024.116312_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23345","article-title":"An ensemble approach of urine sediment image analysis and NMP22 test for detection of bladder cancer cells","volume":"34","author":"Cho","year":"2020","journal-title":"J. Clin. Lab Anal."},{"issue":"10","key":"10.1016\/j.biopha.2024.116312_bib49","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/j.1464-410X.2009.08360.x","article-title":"Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection","volume":"103","author":"Lotan","year":"2009","journal-title":"BJU Int."},{"issue":"12","key":"10.1016\/j.biopha.2024.116312_bib50","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11934-017-0748-x","article-title":"Recent developments in the search for urinary biomarkers in bladder cancer","volume":"18","author":"Leiblich","year":"2017","journal-title":"Curr. Urol. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib51","doi-asserted-by":"crossref","first-page":"242","DOI":"10.14712\/fb2011057060242","article-title":"Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness","volume":"57","author":"Feng","year":"2011","journal-title":"Folia Biol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib52","first-page":"422","article-title":"High expression level of BLCA-4 correlates with poor prognosis in human bladder cancer","volume":"5","author":"Zhao","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib53","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.urolonc.2007.06.002","article-title":"UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing","volume":"26","author":"Hajdinjak","year":"2008","journal-title":"Urol. Oncol."},{"issue":"21","key":"10.1016\/j.biopha.2024.116312_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215423","article-title":"UroVysion(TM) Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives","volume":"14","author":"Ke","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib55","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.21037\/tau-20-1207","article-title":"UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives","volume":"10","author":"Nagai","year":"2021","journal-title":"Transl. Androl. Urol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116312_bib56","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/ijc.30013","article-title":"Apolipoproteins, lipids and risk of cancer","volume":"138","author":"Borgquist","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2024.116312_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081097","article-title":"Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer","volume":"11","author":"Georgila","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib58","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbrc.2014.03.053","article-title":"Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis","volume":"446","author":"Li","year":"2014","journal-title":"Biochem Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2024.116312_bib59","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2147\/CMAR.S165213","article-title":"Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients","volume":"10","author":"Shang","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"15","key":"10.1016\/j.biopha.2024.116312_bib60","doi-asserted-by":"crossref","first-page":"13539","DOI":"10.18632\/oncotarget.3841","article-title":"Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma","volume":"6","author":"Kumar","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib61","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.urology.2015.07.036","article-title":"The diagnostic and prognostic performance of urinary FGFR3 mutation analysis in bladder cancer surveillance: a prospective multicenter study","volume":"86","author":"Couffignal","year":"2015","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41467-017-00147-w","article-title":"Evasion of immunosurveillance by genomic alterations of PPAR\u03b3\/RXR\u03b1 in bladder cancer","volume":"8","author":"Korpal","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib63","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41467-018-08157-y","article-title":"Recurrent activating mutations of PPAR\u03b3 associated with luminal bladder tumors","volume":"10","author":"Rochel","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib64","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85902","article-title":"Claudin-low bladder tumors are immune infiltrated and actively immune suppressed","volume":"1","author":"Kardos","year":"2016","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2217\/bmm.15.120","article-title":"FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence","volume":"10","author":"Blanca","year":"2016","journal-title":"Biomark. Med."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib66","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/CBM-182143","article-title":"Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy","volume":"26","author":"Liu","year":"2019","journal-title":"Cancer Biomark."},{"issue":"5-6","key":"10.1016\/j.biopha.2024.116312_bib67","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000327214","article-title":"A six-week course of bacillus Calmette-Gu\u00e9rin prophylaxis is insufficient to prevent tumor recurrence in nonmuscle invasive bladder cancer with strong-positive expression of p53","volume":"79","author":"Oh","year":"2010","journal-title":"Oncology"},{"issue":"7","key":"10.1016\/j.biopha.2024.116312_bib68","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4161\/cc.24128","article-title":"Dissecting the pathways that destabilize mutant p53: the proteasome or autophagy?","volume":"12","author":"Choudhury","year":"2013","journal-title":"Cell Cycle"},{"issue":"10","key":"10.1016\/j.biopha.2024.116312_bib69","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/dna.2015.2868","article-title":"microRNA-21 Regulates cell proliferation and migration and cross talk with PTEN and p53 in bladder cancer","volume":"34","author":"Lei","year":"2015","journal-title":"DNA Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1074\/mcp.M113.030254","article-title":"Extensive post-translational modification of active and inactivated forms of endogenous p53","volume":"13","author":"DeHart","year":"2014","journal-title":"Mol. Cell Proteom."},{"issue":"12","key":"10.1016\/j.biopha.2024.116312_bib71","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1093\/nar\/gku501","article-title":"Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters","volume":"42","author":"Loughery","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.176","article-title":"Palmdelphin, a novel target of p53 with Ser46 phosphorylation, controls cell death in response to DNA damage","volume":"5","author":"Dashzeveg","year":"2014","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.biopha.2024.116312_bib73","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/s41388-018-0521-8","article-title":"mTOR kinase leads to PTEN-loss-induced cellular senescence by phosphorylating p53","volume":"38","author":"Jung","year":"2019","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib74","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1084\/jem.20171207","article-title":"PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo","volume":"215","author":"Parisotto","year":"2018","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib75","first-page":"287","article-title":"Immunosuppressive effects and potent anti-tumor efficacy of mTOR inhibitor everolimus in breast tumor-bearing mice","volume":"21","author":"Rostamzadeh","year":"2022","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib76","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/PAI.0000000000000193","article-title":"High coexpression of runt-related transcription factor 2 (RUNX2) and p53 independently predicts early tumor recurrence in bladder urothelial carcinoma patients","volume":"24","author":"Abdelzaher","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib77","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/15321819.2014.899254","article-title":"Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma","volume":"35","author":"Ben Abdelkrim","year":"2014","journal-title":"J. Immunoass. Immunochem."},{"key":"10.1016\/j.biopha.2024.116312_bib78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12957-016-0890-9","article-title":"p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis","volume":"14","author":"Du","year":"2016","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib79","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2174\/1574888X10666150630111618","article-title":"PPAR\u03b3 and its ligands: potential antitumor agents in the digestive system.","volume":"11","author":"Shu","year":"2016","journal-title":"Curr. Stem Cell Res. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib80","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1389450118666170622091333","article-title":"Advances on PPAR\u03b3 research in the emerging era of precision medicine","volume":"19","author":"Lu","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.biopha.2024.116312_bib81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2018.01.018","article-title":"The influence of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligands on cancer cell tumorigenicity","volume":"649","author":"Yousefnia","year":"2018","journal-title":"Gene"},{"issue":"13","key":"10.1016\/j.biopha.2024.116312_bib82","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.7150\/jca.42663","article-title":"The role and function of PPAR\u03b3 in bladder cancer","volume":"11","author":"Peng","year":"2020","journal-title":"J. Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2024.116312_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236040","article-title":"Alterations of chromatin regulators in the pathogenesis of urinary bladder urothelial carcinoma","volume":"13","author":"Hoffmann","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib84","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.juro.2012.07.109","article-title":"Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Gu\u00e9rin bladder cancer therapy","volume":"188","author":"Langle","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2024.116312_bib85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2018.01.036","article-title":"PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy","volume":"823","author":"To","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib86","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12885-019-5426-6","article-title":"PPAR\u03b3 activation serves as therapeutic strategy against bladder cancer via inhibiting PI3K-Akt signaling pathway","volume":"19","author":"Lv","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib87","first-page":"3177","article-title":"Heterogeneity of PTEN and PPAR-\u03b3 in cancer and their prognostic application to bladder cancer.","volume":"18","author":"Zhang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.biopha.2024.116312_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.681377","article-title":"Transcription factors: the fulcrum between cell development and carcinogenesis","volume":"11","author":"Islam","year":"2021","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116312_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091318","article-title":"PTEN Alterations as a potential mechanism for tumor cell escape from PD-1\/PD-L1 inhibition","volume":"11","author":"Cretella","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib90","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","article-title":"Targeting PI3K\/AKT\/mTOR pathway in non small cell lung cancer","volume":"90","author":"Fumarola","year":"2014","journal-title":"Biochem Pharmacol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116312_bib91","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/carcin\/bgy086","article-title":"Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex","volume":"39","author":"Gkountakos","year":"2018","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib92","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1038\/s41598-018-22289-7","article-title":"Loss of PTEN-assisted G2\/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer","volume":"8","author":"Mansour","year":"2018","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.biopha.2024.116312_bib93","first-page":"6008","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin. Cancer Res.\u00a0Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116312_bib94","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7150\/jca.31422","article-title":"Cryptotanshinone Inhibites Bladder Cancer Cell Proliferation and Promotes Apoptosis via the PTEN\/PI3K\/AKT Pathway","volume":"11","author":"Liu","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2024.116312_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173226","article-title":"PTEN: What we know of the function and regulation of this onco-suppressor factor in bladder cancer?","volume":"881","author":"Ashrafizadeh","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib96","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13046-019-1262-4","article-title":"USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer","volume":"38","author":"Man","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116312_bib97","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2020.04.023","article-title":"Non-coding RNA in bladder cancer","volume":"485","author":"Li","year":"2020","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib98","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijc.29041","article-title":"Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer","volume":"136","author":"Jiang","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"25","key":"10.1016\/j.biopha.2024.116312_bib99","doi-asserted-by":"crossref","first-page":"40832","DOI":"10.18632\/oncotarget.16586","article-title":"Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer","volume":"8","author":"Du","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biopha.2024.116312_bib100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4111\/kju.2013.54.11.791","article-title":"Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer","volume":"54","author":"Kim","year":"2013","journal-title":"Korean J. Urol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116312_bib101","first-page":"645","article-title":"Evaluation of miR-182\/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer","volume":"19","author":"Chen","year":"2016","journal-title":"Arch. Iran. Med."},{"key":"10.1016\/j.biopha.2024.116312_bib102","article-title":"PTEN regulatory functions in tumor suppression and cell biology","volume":"10","author":"Chu","year":"2004"},{"issue":"8","key":"10.1016\/j.biopha.2024.116312_bib103","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1002\/cam4.2664","article-title":"LncRNA growth arrest-specific transcript 5 targets miR-21 gene and regulates bladder cancer cell proliferation and apoptosis through PTEN","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-018-0771-7","article-title":"Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17\/miR-224 and regulating p21, PTEN expression","volume":"17","author":"Yang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.116312_bib105","doi-asserted-by":"crossref","first-page":"11805","DOI":"10.2147\/OTT.S231489","article-title":"miRNAs: a promising target in the chemoresistance of bladder cancer","volume":"12","author":"Cai","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2024.116312_bib106","article-title":"Expression profile of microRNAs in bladder cancer and their application as biomarkers","volume":"131","author":"Taheri","year":"2020","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13277-014-2617-2","article-title":"A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN\/PI3K\/AKT\/mTOR axis","volume":"36","author":"Yang","year":"2015","journal-title":"Tumour Biol.\u00a0J. Int. Soc. Oncodev. Biol. Med."},{"issue":"24","key":"10.1016\/j.biopha.2024.116312_bib108","article-title":"MiR-103\/107 induces tumorigenicity in bladder cancer cell by suppressing PTEN","volume":"22","author":"Yu","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib109","first-page":"4223","article-title":"Enhanced plasma miR-26a-5p promotes the progression of bladder cancer via targeting PTEN","volume":"16","author":"Wang","year":"2018","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-019-1040-0","article-title":"Circular RNA circSLC8A1 acts as a sponge of miR-130b\/miR-494 in suppressing bladder cancer progression via regulating PTEN","volume":"18","author":"Lu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010078","article-title":"Genome-Wide Screen of miRNAs and Targeting mRNAs Reveals the Negatively Regulatory Effect of miR-130b-3p on PTEN by PI3K and Integrin \u03b21 Signaling Pathways in Bladder Carcinoma","volume":"18","author":"Lv","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib112","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41420-021-00665-z","article-title":"Biological functions and clinical significance of long noncoding RNAs in bladder cancer","volume":"7","author":"Zhang","year":"2021","journal-title":"Cell death Discov."},{"key":"10.1016\/j.biopha.2024.116312_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119948","article-title":"Long non-coding RNAs as new players in bladder cancer: Lessons from pre-clinical and clinical studies","volume":"288","author":"Mirzaei","year":"2022","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.116312_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092531","article-title":"LncRNA RP11-79H23.3 Functions as a Competing Endogenous RNA to Regulate PTEN Expression through Sponging hsa-miR-107 in the Development of Bladder Cancer","volume":"19","author":"Chi","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00438-019-01620-5","article-title":"Downregulation of LncRNA GAS5 promotes liver cancer proliferation and drug resistance by decreasing PTEN expression","volume":"295","author":"Wang","year":"2020","journal-title":"Mol. Genet. Genom."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib116","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.bbrc.2018.07.120","article-title":"LncRNA LINC00641 predicts prognosis and inhibits bladder cancer progression through miR-197-3p\/KLF10\/PTEN\/PI3K\/AKT cascade","volume":"503","author":"Li","year":"2018","journal-title":"Biochem Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2024.116312_bib117","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/jcp.29025","article-title":"MEG3 interacted with miR-494 to repress bladder cancer progression through targeting PTEN","volume":"235","author":"Shan","year":"2020","journal-title":"J. Cell Physiol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116312_bib118","first-page":"3370","article-title":"Mechanism of lncRNA DUXAP8 in promoting proliferation of bladder cancer cells by regulating PTEN","volume":"22","author":"Lin","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.biopha.2024.116312_bib119","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gene.2018.07.041","article-title":"Transcriptomic analysis of high-throughput sequencing about circRNA, lncRNA and mRNA in bladder cancer","volume":"677","author":"Li","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.biopha.2024.116312_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.704703","article-title":"Biological roles and clinical significance of exosome-derived noncoding RNAs in bladder cancer","volume":"11","author":"Tong","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2024.116312_bib121","article-title":"Biomarkers in bladder cancer surveillance","volume":"8","author":"Sugeeta","year":"2021"},{"issue":"4","key":"10.1016\/j.biopha.2024.116312_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041713","article-title":"Role of exosomal miRNA in bladder cancer: a promising liquid biopsy biomarker","volume":"22","author":"Piao","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116312_bib123","article-title":"Combination of urine exosomal mRNAs and lncRNAs as novel diagnostic biomarkers for bladder cancer","volume":"11","author":"Huang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib124","first-page":"151","article-title":"Bladder cancer cell\u2011secreted exosomal miR\u201121 activates the PI3K\/AKT pathway in macrophages to promote cancer progression","volume":"56","author":"Lin","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13402-020-00500-0","article-title":"Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt\/\u03b2-catenin pathway and upregulating PTEN","volume":"44","author":"Shan","year":"2021","journal-title":"Cell Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116312_bib126","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-22-2213","article-title":"Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance","volume":"83","author":"Zhuang","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib127","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ymthe.2022.01.022","article-title":"Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments","volume":"30","author":"Yang","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12967-022-03508-2","article-title":"Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment","volume":"20","author":"Song","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2024.116312_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1019391","article-title":"Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: from functional roles to clinical significance","volume":"12","author":"Lee","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib130","doi-asserted-by":"crossref","DOI":"10.3390\/antiox10050789","article-title":"Clinical significance of heme oxygenase 1 in tumor progression","volume":"10","author":"Nitti","year":"2021","journal-title":"Antioxidants"},{"issue":"9","key":"10.1016\/j.biopha.2024.116312_bib131","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.humpath.2014.04.020","article-title":"Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer","volume":"45","author":"Kim","year":"2014","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib132","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3892\/ol.2016.5416","article-title":"Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2","volume":"13","author":"Matsuo","year":"2017","journal-title":"Oncol. Lett."},{"issue":"7-8","key":"10.1016\/j.biopha.2024.116312_bib133","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000478018","article-title":"Liquid Biopsy: Current Status and Future Perspectives","volume":"40","author":"Mader","year":"2017","journal-title":"Oncol. Res. Treat."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib134","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40169-020-0257-2","article-title":"Detection of bladder cancer using urinary cell-free DNA and cellular DNA","volume":"9","author":"Ou","year":"2020","journal-title":"Clin. Transl. Med."},{"issue":"6","key":"10.1016\/j.biopha.2024.116312_bib135","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116312_bib136","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.euo.2019.08.004","article-title":"Circulating tumor cell and circulating tumor DNA Assays reveal complementary information for patients with metastatic Urothelial Cancer","volume":"4","author":"Chalfin","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib137","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12870-019-1926-4","article-title":"Genotyping-by-sequencing and SNP-arrays are complementary for detecting quantitative trait loci by tagging different haplotypes in association studies","volume":"19","author":"Negro","year":"2019","journal-title":"BMC Plant Biol."},{"key":"10.1016\/j.biopha.2024.116312_bib138","article-title":"Distinguishing HapMap accessions through recursive set partitioning in hierarchical decision trees","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Plant Sci."},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib139","first-page":"227","article-title":"An experimental study of the effects of SNPs in the TATA boxes of the GRIN1, ASCL3 and NOS1 genes on interactions with the TATA-binding protein","volume":"26","author":"Sharypova","year":"2022","journal-title":"Vavilovskii Zh. Genet Sel."},{"issue":"11","key":"10.1016\/j.biopha.2024.116312_bib140","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/ng.229","article-title":"Sequence variant on 8q24 confers susceptibility to urinary bladder cancer","volume":"40","author":"Kiemeney","year":"2008","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.biopha.2024.116312_bib141","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1007\/s00394-022-02932-w","article-title":"Diet quality, common genetic polymorphisms, and bladder cancer risk in a New England population-based study","volume":"61","author":"Leeming","year":"2022","journal-title":"Eur. J. Nutr."},{"key":"10.1016\/j.biopha.2024.116312_bib142","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.946039","article-title":"Cumulative evidence for relationships between multiple variants in the TERT and CLPTM1L region and risk of cancer and non-cancer disease","volume":"12","author":"Tian","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib143","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12916-022-02366-5","article-title":"Association between circulating vitamin E and ten common cancers: evidence from large-scale Mendelian randomization analysis and a longitudinal cohort study","volume":"20","author":"Xin","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib144","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756287211431976","article-title":"Best practice in the treatment of nonmuscle invasive bladder cancer","volume":"4","author":"Anastasiadis","year":"2012","journal-title":"Ther. Adv. Urol."},{"issue":"19","key":"10.1016\/j.biopha.2024.116312_bib145","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A Review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.biopha.2024.116312_bib146","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2024.116312_bib147","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1002\/1878-0261.13288","article-title":"Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome","volume":"16","author":"Viktorsson","year":"2022","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib148","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12964-021-00768-1","article-title":"Cancer derived exosomes induce macrophages immunosuppressive polarization to promote bladder cancer progression","volume":"19","author":"Jiang","year":"2021","journal-title":"Cell Commun. Signal"},{"issue":"7","key":"10.1016\/j.biopha.2024.116312_bib149","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.497","article-title":"Tumor-derived exosomal BCYRN1 activates WNT5A\/VEGF-C\/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer","volume":"11","author":"Zheng","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.116312_bib150","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1172\/JCI130892","article-title":"Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"10","key":"10.1016\/j.biopha.2024.116312_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102545","article-title":"Immune checkpoint inhibitors as a neoadjuvant\/adjuvant treatment of muscle-invasive bladder cancer: a systematic review","volume":"14","author":"Barone","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116312_bib152","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jare.2021.11.010","article-title":"Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives","volume":"39","author":"Liu","year":"2022","journal-title":"J. Adv. Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.116312_bib153","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.biopha.2024.116312_bib154","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"9","key":"10.1016\/j.biopha.2024.116312_bib155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrurol.2017.82","article-title":"Landmarks in the treatment of muscle-invasive bladder cancer","volume":"14","author":"Lobo","year":"2017","journal-title":"Nat. Rev. Urol."},{"issue":"16","key":"10.1016\/j.biopha.2024.116312_bib156","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165670","article-title":"Evolution of Urothelial bladder cancer in the context of molecular classifications","volume":"21","author":"Minoli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2024.116312_bib157","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.1007\/s11033-023-08689-7","article-title":"Molecular classification of urothelial bladder carcinoma","volume":"50","author":"Schwarzova","year":"2023","journal-title":"Mol. Biol. Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224001938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224001938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:17:05Z","timestamp":1793787425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224001938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":157,"alternative-id":["S0753332224001938"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116312","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116312"}}